Skip to main content

Syntekabio History

Syntekabio
History

2020-Present

2020-NOW
Ushering in a New Era of AI Drug Development

Ushering in a New Era of AI Drug Development

2025

December

Certified as a Family-Friendly Company by the Ministry of Gender Equality and Family, Korea

September

ABSC natural convention-based air circulation system patent registerd

June

Signed a drug development agreement with a U.S. animal pharmaceuticals company

May

Signed a joint service agreement with OCMS Bio for an integrated “One-Shot Screening” platform for ultra-fast antibody drug discovery

March

Official global launch of LM-VS (Language Model Virtual Screening) service based on AI drug discovery language model

Signed a $3.1M drug candidate development agreement with U.S. Pragma Biosciences

Partnered with MSK to co-develop new anti-cancer drug compounds

February

Signed a joint research agreement with PDC*line Pharma for a neoantigen cancer vaccine

January

Obtained Platinum grade certification for eco-friendly green data center at ABS Center

2024

December

Signed a DEEPMATCHER® service provision agreement with RUDACURE

November

Signed 1st service agreement with a US Nasdaq-listed TPD-specialized biotech

September

Signed MOU with Enamine (Ukraine) for compound supply, synthesis, and collaborative AI drug discovery

2023

November

Signed MOU with QIMR Berghofer Medical Research Institute (Australia) for joint drug development and commercialization

September

Completed the AI Bio Supercomputing Center in Dungok, Daejeon

July

Signed MOU with U.S. Metaclipse Therapeutics for joint research on personalized therapeutic cancer vaccines

2022

December

Launched STB CLOUD service in the U.S.

2021

November

Signed MOU with JW Pharmaceutical for innovative drug development

July

Signed strategic MOU with KT to build an AI supercomputing center

Established Syntekabio USA, Inc. (New York)

January

Signed joint research agreement with Hanmi Science for COVID-19 drug repurposing

2020

December

Registered domestic patent for SARS-CoV-2 treatment composition

September

Signed MOU with KIMCo, Naver Business Platform, and AI Center

June

Signed joint research agreement with KRIBB for COVID-19 drug repurposing

Selected by the Ministry of Science and ICT as an excellent case in DNA (Data, Network, AI) innovation companies

2016-2019

2016-2019
Expansion into AI-Based New Drug Development

Expansion into AI-Based New Drug Development

2019

December

Listed on KOSDAQ

June

Raised KRW 19.7 billion in Series C funding led by Yuhan Corporation, Sehan Venture Capital, and Timewise Investment

April

Registered domestic patent for AI-based new drug development system

March

Licensed-in an immune-oncology drug candidate co-discovered with CJ Healthcare

2018

December

Published a paper on integrated genomic core technology in BMC Bioinformatics 2018

Signed a collaboration agreement with Yonsei Severance Hospital Precision Medicine Center

November

Signed joint research agreement with JW Pharmaceutical for predictive biomarkers

September

Applied for domestic patent of AI-based new drug development system

June

Published proof-of-concept paper on deep learning-based drug development model CDRscan in Scientific Reports 2018

Published validation paper on genetic mutation detection algorithm ADIscan in Nucleic Acids Research 2018

May

Raised KRW 12 billion in Series B funding (Smilegate, KDB Industrial Bank, etc.)

Signed a cooperation agreement with Inha University Hospital for cancer-related medical centers

April

Signed joint research and cooperation MOU with Yuhan Corporation

2017

December

Signed research agreement with CJ Healthcare for discovery of drug active compounds

November

Signed joint research MOU with Yonsei Severance Hospital

August

Registered domestic patent for bio big data analysis method

Published clinical validation paper on NGS testing for rare diseases in Scientific Reports 201

June

Obtained GMP certification from the Ministry of Food and Drug Safety (KTC-CAB-179288)

March

Published validation paper on HLAscan accuracy in BMC Bioinformatics 2017

2016

November

Selected as an Excellent AI Company by the Ministry of Science and ICT

June

Obtained “New Health Technology Certification” for genetic disease screening

Raised KRW 6 billion in Series A funding (Altos Ventures, etc.)

May

Awarded “Outstanding Company” at the Korea Biotechnology Awards

January

Registered as a genetic testing institution with the Korea Disease Control and Prevention Agency

2009-2015

2009-2015
Foundation and Accumulation of Core Technology

Foundation and Accumulation of Core Technology

2015

November

Obtained approval from the Ministry of Food and Drug Safety to introduce Dx NGS equipment

May

Registered domestic patent for personalized neo-antigen prediction algorithm

February

Completed beta version of PMAP (Personal Genome Map) automatic generation

2014

October

Registered domestic patent for personalized cancer vaccine system

April

Selected as a laboratory company by the Electronics and Telecommunications Research Institute (ETRI)

March

Registered international patent (WO) for anticancer drug response prediction algorithm

2013

December

Selected as one of the “Top 100 Future Technologies and Leaders for 2020”

September

Registered international patent (WO) for genetic mutation-based anticancer drug efficacy prediction

April

Decision to register RVR DBMS/search system with the U.S. Patent and Trademark Office

2012

July

Registered domestic patent for bio big data-based personalized medicine platform

February

Completed genome analysis platform (NGS-pL)

January

Launched integrated genome service for next-generation personalized medicine genome project

2011

December

Registered domestic patent for pharmacogenomics-based anticancer drug response prediction

June

Registered domestic patent for HLA typing method using genome data

2010

August

Registered domestic patent for pharmacogenomics algorithm

2009

October

Syntekabio, Inc. founded